Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study
| Autor: | Hans J.J.A. Bernsen, Corneel Coens, Denis Lacombe, Carin C.D. van der Rijt, Alba A. Brandes, Fabio Efficace, Andrew Bottomley, Marc Sanson, Cees C. Tijssen, Martin J. van den Bent, Marc Frenay, Murielle Mauer, Martin J B Taphoorn |
|---|---|
| Přispěvatelé: | Medical Oncology, Neurology |
| Rok vydání: | 2007 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Weakness Health Status Oligodendroglioma MEDLINE law.invention Quality of life Randomized controlled trial SDG 3 - Good Health and Well-being law Internal medicine medicine Humans Survival analysis business.industry Brain Neoplasms Cancer Middle Aged medicine.disease Prognosis Survival Analysis Surgery Clinical trial Quality of Life Female medicine.symptom business |
| Zdroj: | Journal of Clinical Oncology, 25, 5731-5737. American Society of Clinical Oncology |
| ISSN: | 0732-183X |
| Popis: | Purpose This is one of a few studies that have explored the value of baseline symptoms and health-related quality of life (HRQOL) in predicting survival in patients with brain cancer. Patients and Methods Baseline HRQOL scores (from the European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire C30 and the EORTC Brain Cancer Module) were examined in 247 patients with anaplastic oligodendrogliomas to determine the relationship with overall survival by using Cox proportional hazards regression models. Refined techniques as the bootstrap resampling procedure and the computation of C indexes and R2 coefficients were used to explore the stability of the models as well as better assess the potential benefit of using HRQOL to predict survival in clinical practice and research. Results Classical analysis controlled for major clinical prognostic factors selected emotional functioning (P = .0016), communication deficit (P = .0261), future uncertainty (P = .0481), and weakness of legs (P = .0001) as statistically significant prognostic factors of survival. However, several issues question the validity of these findings and no single model was found to be preferable over all others. C indexes, which estimate the probability of a model to correctly predict which patient among a randomly chosen pair of patients will survive longer, and R2 coefficients, which measure the proportion of variability explained by the model, did not exhibit major improvement when adding selected or all HRQOL scores to clinical factors. Conclusion While classical techniques lead to positive results, more refined analyses suggest that baseline HRQOL scores add relatively little to clinical factors to predict survival. These results may have implications for future use of HRQOL as a prognostic factor for patients with cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|